Literature DB >> 25312828

SMARCB1 deletion by a complex three-way chromosomal translocation in an extrarenal malignant rhabdoid tumor.

Armita Bahrami1, Seungjae Lee2, Kari D Caradine3, Susana C Raimondi2, Andrew L Folpe4.   

Abstract

Rhabdoid tumors (RTs) are highly aggressive malignant neoplasms of early childhood that arise in the kidney, brain, and extrarenal sites. The disease is genetically defined by biallelic disruption of the SMARCB1/INI1/SNF5 tumor suppressor gene, a core component of the ATP-dependent chromatin remodeling SWI/SNF complex. The molecular changes leading to SMARCB1 alterations in RTs are heterogeneous, including germline or constitutional inactivating mutations, partial or total gene deletions, copy number neutral loss of heterozygosity, and, less commonly, reciprocal translocations. We report a novel three-way chromosomal rearrangement, which was identified by conventional cytogenetic and sequential fluorescence in situ hybridization studies as the underlying molecular mechanism of the loss of SMARCB1 in an extrarenal RT. This case highlights the heterogeneity of genetic events that may lead to the loss of SMARCB1 and the development of RTs.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  FISH; INI1; Rhabdoid tumor; SMARCB1; conventional cytogenetic; sequential G-banded FISH

Mesh:

Substances:

Year:  2014        PMID: 25312828     DOI: 10.1016/j.cancergen.2014.08.002

Source DB:  PubMed          Journal:  Cancer Genet


  2 in total

1.  Case Analysis of 14 Children with Malignant Rhabdoid Tumor of the Kidney.

Authors:  Jing Li; Weiling Zhang; Huimin Hu; Yi Zhang; Yizhuo Wang; Huali Gu; Dongsheng Huang
Journal:  Cancer Manag Res       Date:  2021-06-21       Impact factor: 3.989

2.  Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group.

Authors:  M C Frühwald; K Nemes; H Boztug; M C A Cornips; D G Evans; R Farah; S Glentis; M Jorgensen; K Katsibardi; S Hirsch; K Jahnukainen; I Kventsel; K Kerl; C P Kratz; K W Pajtler; U Kordes; V Ridola; E Stutz; F Bourdeaut
Journal:  Fam Cancer       Date:  2021-02-03       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.